SEC Form 4 · accession 0001789970-26-000012
MapLight Therapeutics, Inc. · MPLT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kristopher Hanson
Officer — General Counsel
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 9:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001770069
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Voting Common StockF1,F2 | Jul 15, 2026 | S | 2,147 | $36.00 | D | 160,184 | D | |
| Voting Common StockF1,F3 | Jul 15, 2026 | S | 5,103 | $36.99 | D | 155,081 | D | |
| Voting Common StockF1 | Jul 15, 2026 | S | 10 | $37.54 | D | 155,071 | D | |
| Voting Common StockF1,F4 | Jul 16, 2026 | S | 4,776 | $36.45 | D | 150,295 | D | |
| Voting Common StockF1,F5 | Jul 16, 2026 | S | 3,331 | $37.26 | D | 146,964 | D | |
| Voting Common StockF1 | Jul 16, 2026 | S | 11 | $37.96 | D | 146,953 | D | |
| Voting Common StockF1,F6 | Jul 17, 2026 | S | 1,130 | $37.90 | D | 145,823 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.5338 to $36.5273 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.53 to $37.405 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9075 to $36.9013 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.9082 to $37.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.49 to $37.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.